Custom Search


Wednesday, September 17, 2008

NEW MRI Searchable Database

There is a new service available for hospitals and clincs that can determine the mri safety of implanted devices . check out there website.

The MRI safety status of medical implant devices can be difficult to track because many manufacturers 1.) Change their names; 2) Sell their medical devices to other companies; 3.) Go out of business; 4) Discontinue manufacturing of certain devices; 5.) Merge with other companies; or holding companies move medical device ownership from company to company. Dozens of these transactions transpire annually, bringing confusion and obfuscation to MRI technologists, who need to be certain of an implanted device’s safety status before scanning. After seven or eight years of this merger and acquisition activity, the status of many implants can become impossible to find.

MRI technologists, too often given the sketchiest of information, can spend hours looking for safety status, or materials of construction, to determine if a scan is safe. Even if the search is successful, most sites have no method to ultimately store the data or retrieve it for use later. An MRI site’s source of implant safety information can quickly degrade to a paperback book and an unmanageable manila folder of faxes.

Compounding the problem, are new safety definition standards; more powerful scanners and implants from overseas. Faced with an “MR Conditional” device, technologists must account for the static field strength, spatial gradient field, SAR and time duration of the scan. According to a recent JCAHO Sentinel Event: “All implants should be checked against product labeling or manufacturer literature specific to that implant, or peer-reviewed published data regarding the device or implant in question. Technologists should be provided with ready access to this information.” What JCAHO did not state is where this information is supposed to come from!

A searchable database to store MRI specific information with multiple search options to retrieve manufacturer’s information and published data, would be an invaluable tool to free up technologist’s time and eliminate duplicate research for implant safety information!

MagResource LLC has developed a searchable database to track the MRI safety status of medical implants through this whirlwind of economic and technological turmoil. The Internet database features daily rather than yearly updates to provide site-users with instant access to the latest information. User sites enter the Online Database without login or password. When a device is not found in the database, MagResource will endeavor to find it. Free trials and in-service for MRI sites at:

Saturday, September 13, 2008

Top 13 Reasons to Date an X-ray Tech

1. We do our best work in the dark

2. We can see through your clothes
3. We know all the positions
4. We are well developed
5. The chemistry is always right
6. We know what buttons to push
7. We have all the right techniques
8. We know how to warm up a tube
9. We know how to get the best penetration
10. When you need it now, we make it wet.1
1. Human anatomy is common knowledge.
12. We do it on the table and sometimes we slip it in the bucky.
13. Radiation physics: Hard Beam + Tight Collimation = Adequate penetration

Bayer and Epix to part ways over vasovist.

Bayer Schering Pharma will transfer the worldwide commercial rights for the novel blood pool magnetic resonance angiography (MRA) agent, Vasovist(R) (gadofosveset trisodium) to EPIX. Thecollaboration agreementbetween the two parties will terminate effectiveMarch 1, 2009; until that time, Bayer Schering Pharma will continue to provide continued supply of Vasovist in the 19 countries where it is currently marketed.
"We are pleased to regain complete worldwide commercial rights for Vasovist which has a PDUFA date of December 31, 2008," said Elkan Gamzu, Ph.D., interim chief executive officer of EPIX. "Pending FDA approval, Vasovist is positioned to become the first MRA contrast agent approved in the United States and it could be launched in 2009. Our goal remains to maximize the commercial value of Vasovist and we are committed to executing our monetization strategy which includes finding a marketing and commercialization partner for Vasovist."
"Vasovist is a first-in-class blood specific MRA contrast agent with several distinctive characteristics that we believe may allow it to become a market leader in the United States," added Chen Schor, chief business officer of EPIX. "Vasovist has demonstrated good resolution angiography, a high signal per dose, a long imaging window timeframe and single-dose imaging of multiple vessel beds. We believe these characteristics coupled with a streamlined commercial rights profile should make this an appealing opportunity for a company interested in building or strengthening its competitive position in the MRA market."


MRI Nueroarm Video